News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer
Praveen Kumar Marimuthu/X
May 1, 2025, 09:14

Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer

Praveen Kumar Marimuthu, DM Resident in Medical Oncology at Christian Medical College and Hospital, shared an article by Rebecca Kristeleit, et al. on X:

“Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer.

  • 12-wk PFS: 42%.
  • ORR: 25%.
  • Median DOR: 13.1 mo.
  • Median OS: 14.8 mo.”

Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer

Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical Trial.

Journal: Jama Network

Authors: Rebecca Kristeleit, Michael-John Devlin, Andrew Clamp, Charlie Gourley, René Roux, Marcia Hall, Rachel Nirsimloo, Valentinos Kounnis, Lesley Sage, Priya Narayanan, C. Simon Herrington, Rupali Arora, Laura Farrelly, Laura Hughes, Nicholas Counsel, Rowan E. Miller, et al.

You can Read the Full Article on Journal of JAMA NETWORK.

Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer

More posts featuring Praveen Kumar Marimuthu.

Advanced Clear Cell Gynecological Cancer Andrew Clamp C. Simon Herrington cancer Charlie Gourley Christian Medical College and Hospital clinical trial fight against cancer Global fight against cancer Gynecological Cancer JAMA Network Laura Farrelly Laura Hughes Lesley Sage Marcia Hall MedOnc Michael-John Devlin Nicholas Counsel OncoDaily Oncology pembrolizumab Praveen Kumar Marimuthu Priya Narayanan Rachel Nirsimloo Rebecca Kristeleit René Roux Rowan E. Miller Rupali Arora Valentinos Kounnis
Special Coverage
Blog
Jun 16, 2025, 07:42
Han Chong Toh: Weekend in Seoul Giving a Keynote On AI in Oncology and Cancer Care
Blog
Jun 16, 2025, 07:35
Ioana Stoenescu: Racing for the Cure and Standing United Against Breast Cancer
Insight
Jun 16, 2025, 07:32
Amgen Named Among World’s Greenest Companies by Newsweek for 2025
Blog
Jun 16, 2025, 07:20
Giannis Mountzios: First-Ever Summer School on AI Applications in Cancer Research
Insight
Jun 16, 2025, 07:20
Hilal Lashuel: The Special Lancet Oncology Issue on Cancer Control in the Middle East
Science
Jun 16, 2025, 07:06
DNA Differences May Explain Why Some Melanoma Patients Don’t Respond to Immunotherapy - CRI
Blog
Jun 16, 2025, 06:42
Registration is Open for the Multidisciplinary Management of Stage III and IVa Thymoma - IASLC
Blog
Jun 16, 2025, 06:26
Amy Moore: Honoring My Dad and Hoping to Live Up to the Example He Set on My First Father’s Day Without Him
Blog
Jun 16, 2025, 04:42
Saddened by the Passing of Leonard Lauder, a Visionary Leader and Beloved Honorary Chairman - BCRF
Blog
Jun 16, 2025, 04:34
Miguel Bronchud: What Can Cancer Learn from the Placenta? Introducing the PIES Hypothesis
Blog
Jun 16, 2025, 04:24
Pashtoon Kasi: Discussing the Troubling Rise of Cancer in Young Adults
Blog
Jun 16, 2025, 04:16
Talha Badar: TKI Selection Based on Mutation Profiles in CML at EHA 2025